请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
banner
当前位置: 首页 > 产品中心 > Angiogenesis > MedKoo/AZD-4547featured/50mg/204550

MedKoo/AZD-4547featured/50mg/204550

  • 产品编号: 204550
  • 美  元  价: $150.00
  • 市  场  价: ¥3000.00
  • 品       牌:
  • 产       地: 美国(厂家直采)
  • 公       司: MedKoo Biosciences, Inc
  • 产品分类:
  • 公司分类: Angiogenesis
MedKoo/AZD-4547featured/50mg/204550
  • MedKoo/AZD-4547featured/50mg/204550
商品介绍

AZD-4547
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:204550

CAS#:1035270-39-3

Description:AZD4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.

Price and Availability

SizePriceShipping out timeQuantity
50mgUSD 150Same day
100mgUSD 250Same day
200mgUSD 450Same day
500mgUSD 750Same day
1gUSD 1250Same day
2gUSD 2150Same day
5gUSD 38502 weeks
10gUSD 59502 weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

AZD-4547, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 204550Name: AZD-4547CAS#: 1035270-39-3Chemical Formula: C26H33N5O3Exact Mass: 463.25834Molecular Weight: 463.57192Elemental Analysis:C, 67.36; H, 7.18; N, 15.11; O, 10.35

Related CAS #:1035270-39-31394854-62-6

Synonym:AZD4547; AZD-4547; AZD 4547.

IUPAC/Chemical Name:N-(5-(3,5-dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3S,5R)-3,5-dimethylpiperazin-1-yl)benzamide

InChi Key:VRQMAABPASPXMW-HDICACEKSA-N

InChi Code:InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+

SMILES Code:O=C(NC1=NNC(CCC2=CC(OC)=CC(OC)=C2)=C1)C3=CC=C(N4C[C@H](C)N[C@H](C)C4)C=C3

Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot#CRB70207View CoA: current batch, Lot# CT10716View CoA: current batch, Lot# CRB30604

QC Data:
View QC data: current batch, Lot#CRB70207View QC data: current batch, Lot# CT10716View QC data: current batch, Lot# CRB30604

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

Related CAS#Sci-Finder listed CAS#1394854-62-6for AZD-4547ChemIDplus listed CAS#1035270-39-3 for AZD-4547, see website: https://chem.nlm.nih.gov/chemidplus/rn/1035270-39-3 According to Sci-Finder, Chemical name for CAS#1394854-62-6:N-[3-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl]-4-(3,5-dimethyl-1-piperazinyl)benzamideChemical name for CAS#1035270-39-3:rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide

References

1: Ramsey MR, Wilson C, Ory B, Rothenberg SM, FaquinW, Mills AA, Ellisen LW. FGFR2 signaling underlies p63 oncogenicfunction in squamous cell carcinoma. J Clin Invest. 2013 Aug1;123(8):3525-38. doi: 10.1172/JCI68899. Epub 2013 Jul 8. PubMed PMID:23867503; PubMed Central PMCID: PMC3726171.

2: Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. AutocrineIGF-I/insulin receptor axis compensates for inhibition of AKT inER-positive breast cancer cells with resistance to estrogen deprivation.Breast Cancer Res. 2013 Jul 11;15(4):R55. [Epub ahead of print] PubMedPMID: 23844554.

3: Katoh M, Nakagama H. FGF Receptors: Cancer Biology and Therapeutics.Med Res Rev. 2013 May 21. doi: 10.1002/med.21288. [Epub ahead of print]PubMed PMID: 23696246.

4: Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA,Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. A mechanism ofresistance to gefitinib mediated by cellular reprogramming and theacquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013Mar 25;2:e39. doi: 10.1038/oncsis.2013.4. PubMed PMID: 23552882; PubMedCentral PMCID: PMC3641357.

5: Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K,Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E,Zhang X, Ji Q. FGFR2 gene amplification in gastric cancer predictssensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res.2013 May 1;19(9):2572-83. doi: 10.1158/1078-0432.CCR-12-3898. Epub 2013Mar 14. PubMed PMID: 23493349.

6: Zhao R, Xie X, Shen GX. Effects of glycated low-density lipoproteinon cell viability, proliferation, and growth factors of mouse embryofibroblasts. Can J Physiol Pharmacol. 2013 Jan;91(1):64-70. doi:10.1139/cjpp-2012-0234. Epub 2013 Jan 21. PubMed PMID: 23369077.

7: Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y,Liu K, Dong Z, Zhu G, Qian Z, Tang L, Schöttle J, Zhan P, Ji Q, KilgourE, Smith PD, Brooks AN, Thomas RK, Gavine PR. Translating thetherapeutic potential of AZD4547 in FGFR1-amplified non-small cell lungcancer through the use of patient-derived tumor xenograft models. ClinCancer Res. 2012 Dec 15;18(24):6658-67. doi:10.1158/1078-0432.CCR-12-2694. Epub 2012 Oct 18. Erratum in: Clin CancerRes. 2013 Jul 1;19(13):3714. Schöttle, Jakob [added]. PubMed PMID:23082000.

8: Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L,Hampson M, Gavine PR, Cook SJ. Tumour cell responses to new fibroblastgrowth factor receptor tyrosine kinase inhibitors and identification ofa gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.Oncogene. 2013 Jun 20;32(25):3059-70. doi: 10.1038/onc.2012.319. Epub2012 Aug 6. PubMed PMID: 22869148.

9: Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM,Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, RiccardiR, Brat DJ, Guha A, Aldape K, Golfinos JG, Zagzag D, Mikkelsen T,Finocchiaro G, Lasorella A, Rabadan R, Iavarone A. Transforming fusionsof FGFR and TACC genes in human glioblastoma. Science. 2012 Sep7;337(6099):1231-5. doi: 10.1126/science.1220834. Epub 2012 Jul 26.PubMed PMID: 22837387; PubMed Central PMCID: PMC3677224.

10: Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S,Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T.AZD4547: an orally bioavailable, potent, and selective inhibitor of thefibroblast growth factor receptor tyrosine kinase family. Cancer Res.2012 Apr 15;72(8):2045-56. doi: 10.1158/0008-5472.CAN-11-3034. Epub 2012Feb 27. PubMed PMID: 22369928.

品牌介绍


MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。

MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。




蚂蚁淘(ebiomall)作为一家生命科学领域的垂直电商平台,公司专注生物医学科研用品的全球导购和品牌推广,为海内外厂方与代理经销商搭建跨境贸易系统和交流平台。产品齐全,200+分类,1000+品牌,500万+产品信息。100%正品,专业售后,到货快,在线下单, 简单轻松,节省科学家宝贵的科研时间。为您竭诚服务!

【订购】蚂蚁淘生物科技  联系方式:4000-520-616

更多产品,更多优惠!请联系我们!

苏州蚂蚁淘生物科技有限公司

免费热线:4000-520-616

官网:https://www.ebiomall.cn/



MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采模式 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔
在线客服
客服电话

4000-520-616

0512-67156496